Search Results
60 protocol(s) meet the specified criteria
100308Not Open *
Phase I/IB, Open-Label, Multicenter, Dose-Escalation Study of NIS793 in Combination with PDR001 in Adult Patients with Advanced Malignancies

100703Open  
Phase IA/b Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of OMP-313M32 Administered as a Single Agent on in combination with Nivolumab to Subjects with Locally Advanced or Metastatic Solid Tumors

100704Open  
Phase I/II, Open-Label, Dose-Escalation, Safety, Tolerability, and Efficacy Study of Epacadostat in Combination with a PD-1 Inhibitor and Chemotherapy in Subjects with Advanced or Metastatic Solid Tumors (ECHO-207)

100890Open  
Phase IB (Open-Label) / Phase II (Randomized, Double-Blinded) Study Evaluating Nab-Paclitaxel and Gemcitabine with or without Olaratumab in the Treatment of First-Line Metastatic Pancreatic Cancer

101274Not Open *
Phase I Study Evaluating the Safety, Pharmacokinetics and Anti-Tumor Activity of ABBV-176 in Subjects with Advanced Solid Tumors likely to Express Prolactin Receptor (PRLR)

101981Open  
Phase I/II Study to Assess the Safety and Efficacy of Intratumoral IMO-2125 in Combination with Ipilimumab or Pembrolizumab in Patients with Metastatic Melanoma

102309Open  
Phase IB, Open-Label, Dose-Finding Study to Evaluate the Safety and Tolerability of Cabometyx and Avelumab in Patients with Metastatic Renal Cell Carcinoma (mRCC)

102829Open  
Phase IB Dose-Escalation Study of Cabozantinib Administered in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors

102932Open  
Phase I Trial of MEDI-570 in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) Follicular Variant and Angioimmunoblastic T-Cell Lymphoma (AITL)

103123Open  
Multicenter, Phase I, Open-Label Study of DCC-2618 to Assess Safety, Tolerability, Efficacy, and Pharmacokinetics in Patients with Advanced Malignancies

103657Open  
Exploratory Phase IB Study to Assess the Effects of Merestinib on Bone Metastases in Subjects with Breast Cancer

103695Open  
Pilot Trial Evaluating the Combination of Reolysin and Carfilzomib in Multiple Myeloma

103706Open  
Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of ARQ 531 in Selected Subjects with Relapsed or Refractory Hematologic Malignancies

103711Not Open *
Phase I and Expansion Cohort Study of Adjuvant Cisplatin, Intensity-Modulated Radiotherapy, and MK-3475 (Pembrolizumab) in High-Risk Head and Neck Squamous Cell Carcinoma (HNSCC)

103722Open  
Phase I, First-in-Man, Multicenter, Open-Label, Dose-Escalation Study of Single-Agent GBR 1302 in Subjects with HER2 Positive Cancers

103837Open  
Phase IB/II Study to Assess the Safety, Tolerability, and Efficacy of BGB-290 in Combination with Radiation Therapy and/or Temozolomide in Subjects with First-Line or Recurrent/Refractory Glioblastoma

103945Open  
Phase I Open-Label Trial of a Combination of Nivolumab and Bevacizumab in Patients with Advanced and/or Metastatic Hepatocellular Carcinoma

104258Open  
Phase I/II, Open-Label, Dose-Finding, Proof of Concept, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CX-2009 in Adults with Metastatic or Locally Advanced Unresectable Solid Tumors

104564Not Open *
Phase I/II Trial of ABT-888, an Inhibitor of Poly (ADP-ribose) Polymerase (PARP), and Topotecan (TPT) in Patients with Solid Tumors (Phase I) and Relapsed Ovarian Cancer or Primary Peritoneal Cancer (Phase II) after Prior Platinum Containing First-Line Chemotherapy

104630Open  
Phase I Dose Escalation Study Evaluating the Safety and Tolerability of PF-06804103 in Patients with Human Epidermal Growth Factor Receptor 2 (HER2) Positive Solid Tumors (FIM)

105164Open  
Phase IB/II Study of BMS-813160 in Combination with Chemotherapy or Nivolumab in Patients with Advanced Solid Tumors

105925Not Open *
Phase I First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects with Relapsed or Refractory Multiple Myeloma and Subjects with Relapsed or Refractory Acute Myeloid Leukemia

107029Open  
Two-Part Phase I/II Study to Determine Safety, Tolerability, Pharmacokinetics, and Activity of K0706, a Novel Tyrosine Kinase Inhibitor (TKI), in Healthy Subjects and in Subjects with Chronic Myeloid Leukemia (CML) or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

108884Open  
Phase I/II Open Label Study of the Safety and Efficacy of Apatinib Administered to Patients with Advanced Malignancies to Improve Sensitivity to Pembrolizumab in the Second- or Later-Line Setting (APPEASE)

108914Open  
First-In-Human, Open-Label, Dose-Escalation Trial with Expansion Cohorts to Evaluate Safety of Axl-Specific Antibody-Drug Conjugate (HuMax®-AXL-ADC) in Patients with Solid Tumors

44704Open  
Assessment of Primary and Metastatic Brain Tumor Hypoxia with 18F-Fluoromisonidazole, [18F]fluoro-2-deoxy-D-glucose (FDG) and [15O]water (H215O)

61077Open  
Phase I/II Study of Treg/Tcon Addback to CD34 Selected Partially Matched Related Donor Stem Cells with Myeloablative Conditioning for High-Risk Hematologic Malignancies

71940Open  
Stereotactic Radiosurgery Dose Escalation for Brain Metastases

76853Open  
Phase I/IB Study of MGCD516 in Patients with Advanced Solid Tumor Malignancies

79885Not Open *
Open-Label, Dose-Escalation and Multicenter Study to Evaluate the Safety and Pharmacokinetics of SAR650984 in Patients with Relapsed/Refractory Multiple Myeloma

80314Open  
Development of Quantitative Imaging Biomarkers for Evaluating Sarcoma Patients

80792Open  
Randomized, Double-Blind, Phase IB/II Study of PF-04449913 in Combination with Azacitidine in Patients with Previously Untreated Intermediate-2 or High-Risk Myelodysplastic Syndrome, Acute Myeloid Leukemia with 20-30% Blasts and Multi-Lineage Dysplasia, or Chronic Myelomonocytic Leukemia

81405Open  
Phase I/IIA Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of PLX8394 in Patients with Advanced, Unresectable Solid Tumors

82831Open  
Phase I/II, Open-Label, Multicenter Study of the Safety and Efficacy of LAG525 Single Agent and in Combination with PDR001 Administered to Patients with Advanced Malignancies

83992Open  
Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BLU-554 in Patients with Hepatocellular Carcinoma and Cholangiocarcinoma

84004Open  
Molecular Analysis for Therapy Choice (MATCH)

86211Open  
Platform Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of INCB Combinations in Advanced Solid Tumors

87144Open  
Phase IB Trial of a Combination of mFOLFIRI with MEK162 in Patients with Advanced KRAS Positive Metastatic Colorectal Cancers

87238Open  
Phase I/II Study of Intratumoral G100 Therapy in Patients with Follicular Non-Hodgkin Lymphoma

87559Open  
Phase I/II Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Seviteronel plus Dexamethasone (SEVI-D) in Subjects with Advanced Breast Cancer

87788Open  
Open-Label, Phase IB Study of ACP-196 Alone or in Combination with Rituximab in Subjects with Follicular Lymphoma

87799Open  
Phase I Dose-Ranging Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MRG-106 following Local Intratumoral and Subcutaneous Injection in Patients with Cutaneous T-Cell Lymphoma (CTCL), Mycosis Fungoides (MF) Sub-Type

88893Open  
Phase IB Study of Intratumoral CAVATAK (Coxsackievirus A21) and Ipilimumab in Patients with Advanced Melanoma

88980Open  
Phase I Dose-Escalation Study Evaluating the Safety and Tolerability of PF-06671008 in Patients with Advanced Solid Tumors

89466Open  
Phase IB, Open-Label, Multicenter, Dose-Escalation Trial of Intratumoral Injections of SD-101 in Combination with Pembrolizumab in Patients with Metastatic Melanoma

89510Open  
STARTRK-2 (Studies of Tumor Alterations Responsive to Targeting Receptor Kinases-2): An Open-Label, Multicenter, Global, Phase II Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

90576Open  
Phase I, Open-Label, Multicenter Study of the Safety and Efficacy of MIW815 (ADU-S100) Administered by Intratumoral Injection to Patients with Advanced/Metastatic Solid Tumors or Lymphomas

93426Open  
Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-Like Protein 3-Expressing Advanced Solid Tumors

94141Not Open *
Phase I, Multicenter, Open-Label Study of Oral ABL001 in Patients with Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

94144Open  
Phase IB, Open-Label, Multicenter Study to Characterize the Safety, Tolerability, and Pharmacodynamics (PD) of PDR001 in Combination with LCL161, Everolimus (RAD001), or Panobinostat (LBH589)

95588Open  
Open-Label, Dose-Finding, and Proof-of-Concept Study of the PD-L1 Probody Therapeutic, CX-072, as a Monotherapy and in Combination with Yervoy® (Ipilimumab) or with Zelboraf® (Vemurafenib) in Anti-PD-1/PD-L1 Inhibitor Naïve Subjects with Advanced or Recurrent Solid Tumors or Lymphomas

95978Open  
Phase IB Study of the Safety and Pharmacokinetics of Atezolizumab (Anti Pd L1 Antibody) Alone or in Combination with an Immumomodulatory Drug and/or Daratumumab in Patients with Multiple Myeloma (Relapsed/Refractory and Post Autologous Stem Cell Transplantation)

95981Open  
Phase IB Study of OMP-305B83 plus FOLFIRI in Subjects with 2nd-Line Metastatic Colorectal Cancer

97412Open  
Open-Label Phase I/II Study of INCB039110 in Combination with Osimertinib in Subjects with Locally Advanced or Metastatic Non-Small Cell Lung Cancer

97417Open  
Phase I/IIA First-In-Human Study of BMS-986207 Monoclonal Antibody Alone and in Combination with Nivolumab in Advanced Solid Tumors

97422Open  
Phase I/IB Study of Subcutaneous Recombinant Human hetIL-15 Alone and in Combination with PDR001 in Adults with Metastatic Cancers

99128Open  
Open-Label Phase I/IIA Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of TRC253, an Androgen Receptor Antagonist, in Patients with Metastatic Castration-Resistant Prostate Cancer

99707Open  
Phase I, Non-Randomized, Open-Label/Phase II Randomized, Blinded Study of ProTmune versus Non-Programmed Mobilized Peripheral Blood Cells for Allogeneic Hematopoietic Cell Transplantation in Adult Subjects with Hematologic Malignancies

99903Open  
Proof-of-Concept, Pilot Study of Pembrolizumab in Patients with Recurrent Malignant Glioma with a Hypermutator Phenotype

99906Open  
Phase I Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors